Table 1.
Percent distribution of selected characteristics at diagnosis in 1,204 women with invasive breast cancer
| |
All women |
Younger women |
Older women |
||||||
|---|---|---|---|---|---|---|---|---|---|
|
(ages 35–49 y) |
(ages 50–64 y) |
||||||||
| |
White |
Black |
Pa |
White |
Black |
Pa |
White |
Black |
Pa |
| n=681 | n=523 | n=345 | n=272 | n=336 | n=251 | ||||
| Study site |
|
|
0.01 |
|
|
0.07 |
|
|
0.09 |
| Los Angeles |
66.7 |
73.2 |
|
64.9 |
71.7 |
|
68.5 |
74.9 |
|
| Detroit |
33.3 |
26.8 |
|
35.1 |
28.3 |
|
31.6 |
25.1 |
|
| Age at diagnosis, years |
|
|
0.004 |
|
|
<0.001 |
|
|
|
| 35-39 |
21.4 |
14.2 |
|
42.3 |
27.2 |
|
- |
- |
|
| 40-44 |
15.9 |
19.5 |
|
31.3 |
37.5 |
|
- |
- |
|
| 45-49 |
13.4 |
18.4 |
|
26.4 |
35.3 |
|
- |
- |
|
| 50-54 |
18.7 |
17.6 |
|
- |
- |
|
37.8 |
36.7 |
0.42 |
| 55-59 |
14.5 |
16.4 |
|
- |
- |
|
29.5 |
34.3 |
|
| 60-64 |
16.2 |
14.0 |
|
- |
- |
|
32.7 |
29.1 |
|
| ER status |
|
|
<0.001 |
|
|
0.05 |
|
|
<0.001 |
| ER- |
36.9 |
48.8 |
|
46.4 |
54.4 |
|
27.1 |
42.6 |
|
| ER+ |
63.1 |
51.2 |
|
53.6 |
45.6 |
|
72.9 |
57.4 |
|
| PR status |
|
|
<0.001 |
|
|
<0.001 |
|
|
<0.001 |
| PR- |
38.5 |
52.4 |
|
42.6 |
54.0 |
|
34.2 |
50.6 |
|
| PR+ |
61.5 |
47.6 |
|
57.4 |
46.0 |
|
65.8 |
49.4 |
|
| HER2 status |
|
|
0.16 |
|
|
0.98 |
|
|
0.04 |
| HER2- |
83.3 |
80.1 |
|
81.2 |
81.3 |
|
85.4 |
78.9 |
|
| HER2+ |
16.7 |
19.9 |
|
18.8 |
18.7 |
|
14.6 |
21.1 |
|
| Subtypes defined by ER/PR/HER2 |
|
|
<0.001 |
|
|
0.12 |
|
|
<0.001 |
| TN |
23.8 |
33.5 |
|
30.4 |
39.0 |
|
17.0 |
27.5 |
|
| Luminal A |
59.5 |
46.7 |
|
50.7 |
42.3 |
|
68.5 |
51.4 |
|
| Luminal B |
9.8 |
10.3 |
|
11.0 |
9.9 |
|
8.6 |
10.8 |
|
| HER2-enriched |
6.9 |
9.6 |
|
7.8 |
8.8 |
|
6.0 |
10.4 |
|
| p53 status |
|
|
<0.001 |
|
|
|
|
|
0.003 |
| p53- |
77.0 |
65.8 |
|
72.5 |
61.0 |
0.003 |
81.6 |
70.9 |
|
| p53+ |
23.0 |
34.2 |
|
27.5 |
39.0 |
|
18.4 |
29.1 |
|
| Subtypes defined by ER/PR/HER2/p53 |
|
|
<0.001 |
|
|
0.03 |
|
|
<0.001 |
| TN/p53- |
14.4 |
16.6 |
|
18.0 |
18.8 |
|
10.7 |
14.3 |
|
| TN/p53+ |
9.4 |
16.8 |
|
12.5 |
20.2 |
|
6.3 |
13.2 |
|
| Luminal A/p53- |
49.9 |
37.7 |
|
41.5 |
31.3 |
|
58.6 |
44.6 |
|
| Luminal A/p53+ |
9.5 |
9.0 |
|
9.3 |
11.0 |
|
9.8 |
6.8 |
|
| Luminal B/p53- |
8.1 |
6.0 |
|
8.4 |
5.2 |
|
7.7 |
6.8 |
|
| Luminal B/p53+ |
1.8 |
4.4 |
|
2.6 |
4.8 |
|
0.9 |
4.0 |
|
| HER2-enriched/p53- |
4.6 |
5.5 |
|
4.6 |
5.9 |
|
4.5 |
5.2 |
|
| HER2-enriched/p53+ |
2.4 |
4.0 |
|
3.2 |
2.9 |
|
1.5 |
5.2 |
|
| Stage |
|
|
<0.001 |
|
|
0.007 |
|
|
0.001 |
| Localized |
63.1 |
51.1 |
|
56.5 |
45.6 |
|
69.9 |
57.0 |
|
| Non-localized |
36.9 |
49.0 |
|
43.5 |
54.4 |
|
30.1 |
43.0 |
|
| Grade |
|
|
<0.001 |
|
|
0.006 |
|
|
<0.001 |
| Low |
12.5 |
8.6 |
|
9.6 |
6.6 |
|
15.5 |
10.8 |
|
| Intermediate |
63.1 |
53.0 |
|
58.6 |
49.3 |
|
67.9 |
57.0 |
|
| High | 24.4 | 38.4 | 31.9 | 44.1 | 16.7 | 32.3 | |||
aP ascertained from Pearson χ2 test. Abbreviations: ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor; TN, triple negative. Note: TN = ER-/PR-/HER2-, Luminal A = ER+ or PR+ plus HER2-, Luminal B = ER+ or PR+ plus HER2+, HER2-enriched = ER-/PR-/HER2+.